Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction

Amit Mahindra¹, Gonzalo Tejeda², Mario Rossi²,³, Omar Janha², Imogen Herbert⁴, Caroline Morris¹, Danielle C. Morgan¹, Wendy B eattle⁵, Augusto C. Montezano⁵, Brian Hudson², Andrew B. Tobin⁵, David Bhella⁴, Rhian M. Touyz⁵, Andrew G. Jamieson¹, George S. Baillie⁵, Connor M. Blair⁵ *

¹ School of Chemistry, University of Glasgow, Glasgow, United Kingdom, ² Institute of Molecular Cell & Systems Biology, School of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³ Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy, ⁴ MRC Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom, ⁵ Institute of Cardiovascular and Medical Sciences, Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom

Abstract

SARS-CoV-2 viral attachment and entry into host cells is mediated by a direct interaction between viral spike glycoproteins and membrane bound angiotensin-converting enzyme 2 (ACE2). The receptor binding motif (RBM), located within the S1 subunit of the spike protein, incorporates the majority of known ACE2 contact residues responsible for high affinity binding and associated virulence. Observation of existing crystal structures of the SARS-CoV-2 receptor binding domain (SRBD)–ACE2 interface, combined with peptide array screening, allowed us to define a series of linear native RBM-derived peptides that were selected as potential antiviral decoy sequences with the aim of directly binding ACE2 and attenuating viral cell entry. RBM1 (16mer): S⁴⁴³KVGGNYNYLYRLFRK⁴⁵⁸, RBM2A (25mer): E⁴⁸⁴GFNCYFPLQSYGFQPTNGVGYQPTNGVGY⁵⁰⁵, RBM2B (20mer): F⁴⁵⁶NCYFPLQSYGFQPTNGVGY⁵⁰⁵ and RBM2A-Sc (25mer): NYGLQSPFGYQETPYPCNFVQYG. Data from fluorescence polarisation experiments suggested direct binding between RBM peptides and ACE2, with binding affinities ranging from the high nM to low μM range (Kₐ = 0.207–1.206 μM). However, the RBM peptides demonstrated only modest effects in preventing SRBD internalisation and showed no antiviral activity in a spike protein trimer neutralisation assay. The RBM peptides also failed to suppress S1-protein mediated inflammation in an endogenously expressing ACE2 human cell line. We conclude that linear native RBM-derived peptides are unable to outcompete viral spike protein for binding to ACE2 and therefore represent a suboptimal approach to inhibiting SARS-CoV-2 viral cell entry. These findings reinforce the notion that larger biologics (such as soluble ACE2, ‘miniproteins’, nanobodies and antibodies) are likely better suited as SARS-CoV-2 cell-entry inhibitors than short-sequence linear peptides.
Introduction

The ongoing COVID19 (SARS-CoV-2) pandemic has resulted in > 235 million confirmed cases and > 4.8 million deaths globally since its outbreak in 2019 [1]. SARS-CoV-2 is a positive sense single stranded RNA virus classified within the betacoronavirus genus, primarily entering the host via epithelial cells within the upper respiratory tract [2]. Host cell invasion of SARS-CoV-2, similar to SARS-CoV-1, relies upon the direct interaction between its spike glycoprotein (S) and the host cell membrane bound angiotensin converting enzyme 2 (ACE2) [3, 4]. Key contact residues within the receptor binding domain (RBD) of SARS-CoV-2 (located within the S1 subunit of the S) play a critical role in mediating high affinity, low nM binding to ACE2. This association drives high viral infection rates and consequential pathogenic severity [5–8]. Neutralising antibodies raised against the RBD, soluble recombinant ACE2 (sACE2), and other related proteins have demonstrated a clear ability to block the RBD–ACE2 protein-protein interaction (PPI) and attenuate viral entry of both SARS-CoV-1 and SARS-CoV-2 strains [9]. These findings highlight the potential of disrupting the RBD–ACE2 protein-protein interaction (PPI) as a promising antiviral therapeutic approach.

Therapies capable of selectively disrupting PPIs represent a highly efficacious approach to treating certain diseases, with several demonstrating clear therapeutic benefit clinically [10]. However, effectively disrupting a PPI is highly challenging. The featureless interface of a PPI typically spans a large surface area (1,500–3,000 Å²), consisting of multiple non-continuous binding sites (also referred to as ‘hot spots’) and no obvious deep binding pocket(s) [11]. This often renders traditional drug discovery approaches, such as competitive small molecules, a suboptimal approach to disrupting a given PPI due to their inability to exploit large surface areas (< 1,000 Å²) [12]. Accordingly, development of PPI inhibitors has shifted focus to larger biologic molecules such as peptides (known as decoy, disruptor or interference peptides) [13]. Decoy peptides are typically designed from native structures containing a given PPI hot spot (s), meaning they possess high selectivity and affinity for their target(s), whilst constituting a low immunogenic risk [14, 15].

Research aimed at developing viral entry peptide inhibitors by competitively targeting the SARS-CoV-2 –ACE2 molecular interaction, has largely focussed on the antiviral potential of ACE2 sequence derived peptides/peptidomimetics [9]. These studies utilised existing co-crystal structures of ACE2 in complex with SARS-CoV-2 S_RBD, to design peptides that contain known RBD contact residues found within the α1 helix of the ACE2 binding interface [16–18]. Resulting antiviral efficacy of these ACE2 peptides varies considerably, depending largely on their size, stability, and secondary structure(s). Conversely, few studies have investigated peptide mimics derived from the SARS-CoV-2 S_RBD sequence as potential antiviral PPI decoys. Notably, co-crystal structures of the SARS-CoV-2 RBD–ACE2 PPI highlight that all known contact residues within ACE2 are incorporated within the receptor binding motif (RBM, N437–Y508) of the S1 subunit [7]. Considering the dense location of these known ACE2-interacting hot spots clusters (Fig 1), the RBM represents a significant region for the rational development of short sequence RBD–ACE2 decoy peptides. Previous work utilising a SARS-CoV-1 spike RBM derived hexapeptide (Y438-K-Y-R-Y-L443) demonstrated a modest ability to directly bind ACE2 (K_d = 46 μM) and inhibit coronavirus NL63 cell entry and subsequent viral replication [19]. Previous work utilising a SARS-CoV-1 spike RBM derived hexapeptide (Y438-K-Y-R-Y-L443) demonstrated a modest ability to directly bind ACE2 (K_d = 46 μM) and inhibit coronavirus NL63 cell entry and subsequent viral replication [19]. Although this peptide was not tested against SARS-CoV-1 viral entry, these findings highlight the possibility for a SARS-CoV-2 RBM-derived peptide to represent a potentially promising approach to the development of novel antiviral decoy peptides. However, as the spike protein corresponding to
SARS-CoV-2 has been shown to bind ACE2 10 times more tightly than SARS-CoV-1, the binding affinity of SARS-CoV-2 derived peptide(s) will need to be significantly higher in order to be competitive against the spike protein [20].

In a unique approach, we have combined peptide array screening and existing co-crystal structures of the SARS-CoV-2 RBD–ACE2 PPI to select a novel set of peptides with potential anti-viral activity. We report on studies that evaluate the peptides’ ability to (i) bind ACE2 directly, (ii) disrupt spike protein mediated internalisation, and (iii) inhibit spike protein induced pro-inflammatory cytokine production in human coronary microvascular epithelial cells (CMEC).

**Materials and methods**

**Peptide array**

Peptide experiments were performed as described previously [21]. SARS-CoV-2 receptor binding motif (RBM) peptides were produced by automatic SPOT synthesis [22, 23]. Peptides were synthesised on continuous cellulose membrane supports using 9-fluorenylmethoxy carbonyl chemistry (Fmoc) by the MultiPep RSi Robot (Intavis). RBM peptide arrays were blocked in 5% BSA in 1X TBS-T for 2 hours, at room temperature. Arrays were overlaid with...
1 μM ACE2-Fc recombinant protein (GenScript) [S1 Fig] overnight, at 4˚C. ACE2-Fc binding to RBM peptides was determined with an α-ACE2 (1:1000; Abcam–ab15348) primary antibody (4˚C, 4 hours), followed by an HRP-conjugated secondary antibody (1:5000; Sigma–A6154, room temperature, 1 hour) and finally ECL detection. All protein and antibody incubation steps were carried out under gentle agitation, and arrays washed following protein and antibody incubation steps in 1X TBS-T. Protein–peptide binding signal was assessed via observational changes in binding signal intensity (not peptide size/shape).

**Peptide synthesis and purification reagents**

Fmoc-protected amino acids were purchased from CEM Corporation, and Pepceuticals. N,N-Dimethylformamide (DMF) and diethyl ether (Et₂O) were purchased from Rathburn. Triisopropylsilane (TIPS), Trifluoroacetic acid (TFA), N,N-Diisopropylethylamine (DIPEA), N,N-diisopropycarbodiimide (DIC), ethyl cyan (hydroxyimino) acetate (Oxyma Pure), fluorescein-5-isothiocyanate (FITC), Fmoc-Lys(Alloc)-OH, Tetrakis(triphenylphosphine)palladium (0) {Pd(PPh₃)₄}, and phenylsilane were purchased from Fluorochem. Morpholine was purchased from Alfa Aesar. Dichloromethane (DCM) was purchased from VWR. Acetonitrile (MeCN) was purchased from Honeywell. TentaGel S RAM resin was purchased from Rapp Polymere. All other reagents were purchased from Sigma Aldrich.

**Solid phase peptide synthesis (SPPS) and peptide modifications**

Peptides were synthesised on a 0.1 mmol scale using either a Biotage Initiator + Alstra (Biotage) or CEM Liberty Blue microwave assisted peptide synthesiser, with a TentaGel S RAM resin (0.24 mmol/g). Coupling of Fmoc-protected amino acids (5 eq, 0.2 M in DMF) and unnatural/orthogonally protected amino acids (2.5 eq, 0.1 M in DMF) was achieved by treatment with DIC (5 eq, 0.5 M in DMF) and Oxyma Pure (5 eq, 0.5 M in DMF) at 90˚C for 2 minutes. β-branched amino acids and those following unnatural amino acids were double coupled. Deprotection was achieved by treatment with morpholine (20 % in DMF with 5 % formic acid, 4 mL) at 90˚C for 1 minute. The resin was washed with DMF between deprotection and coupling (4 x 4 mL), and after coupling (2 x 4 mL).

Peptides requiring N-terminal acetylation were treated on-resin with acetic anhydride (3 eq), DIPEA (4.5 eq) and DMF (7 mL for 0.1 mmol of resin) for 20 minutes with agitation. The resin was then washed with DMF (3 x 5 mL) and DCM (3 x 5 mL) prior to peptide cleavage and global deprotection.

Peptides containing Fmoc-Lys (Alloc)-OH were treated on-resin to selectively remove the Alloc protecting group. Pd (PPh₃)₄ (0.25 eq) and phenylsilane (25 eq) were pre-mixed in DCM (2 mL for 0.1 mmol of resin) and added to the resin, leaving for 4 h with agitation. The resin was then washed with DMF (2 x 5 mL) and DCM (2 x 5 mL) prior to peptide cleavage and global deprotection.

Peptides requiring a C-terminal fluorescent label were treated on-resin with FITC (2 eq), DIPEA (8 eq) and DMF (4 mL for 0.1 mmol of resin) following alloc deprotection of an orthogonally protected Lys. The resin was then washed with DMF (2 x 5 mL) and DCM (2 x 5 mL) prior to peptide cleavage and global deprotection.

**Peptide cleavage and global deprotection**

Peptides were cleaved from the resin using a cocktail of TFA (95%), TIPS (2.5%) and H₂O (2.5%) for 3 hours with agitation. Peptides containing Cysteine (Cys) were cleaved from the resin using a cocktail containing TFA (94%), Ethane dithiol (EDT 2.5%), H₂O (2.5%) and TIPS (1%) for 3 hours with agitation. The resin was subsequently filtered and the TFA
evaporated using a stream of N₂, the peptide precipitated with cold Et₂O and centrifuged (4500 rpm for 5 minutes). Peptides were dissolved in a mixture of H₂O and MeCN with 0.1% TFA and lyophilized on a Christ Alpha 2–4 LO plus freeze dryer.

**Peptide purification [S2–S9 Figs]**

Crude peptides were purified by reverse-phase high-performance liquid chromatography (RP-HPLC) using either an Agilent Technologies 1260 Infinity RP-HPLC system or a Dionex RP-HPLC system with Dionex P680 pumps and a Dionex UVD170U UV-vis detector, each with a Phenomenex Gemini column (5 mm C18, 250 x 21.2 mm). Purified peptides were analysed on a Shimadzu RP-HPLC system with Shimadzu LC-20AT pumps, a Shimadzu SIL20A autosampler and a Shimadzu SPD-20A UV-vis detector using a Phenomenex Aeris column (5 mm C18, 100 Å, 150 x 10 mm). Peptides were eluted with linear gradients at column-dependent flow rates (1 ml/min for the Aeris, 10 mL/min for the Gemini), where buffer A = 0.1% TFA in H₂O and buffer B = 0.1% TFA in MeCN. Liquid chromatography mass spectrometry (LCMS) was performed on a Thermo Scientific LCQ Fleet Ion Trap Mass Spectrometer using positive mode electrospray ionisation (ESI⁺). Where buffer A = 0.1% TFA and 5% MeCN in H₂O and buffer B = 0.1% TFA and 5% H₂O in MeCN, a linear gradient of 0–100% B over 20 min with a flow rate of 1 mL/min was used with a Reprosil-Gold column (3 mm C18, 150 x 4 mm).

**Fluorescent polarisation (FP)**

FP assays were performed as described previously [16]. Briefly, direct binding of purified human ACE2-Fc (Q18 –S470) recombinant protein (GenScript) with fluorescently labelled RBM-derived peptides (FITC) was measured at an excitation/emission wavelength of 485/535nm using a Mithras LB 940 plate reader (Berthold Technologies). RBM-FITC peptides were incubated at a final concentration of 500 nM with increasing concentrations of ACE2 protein (0.012 μM – 6 μM) in PBS, and binding affinity (K_D) was calculated by nonlinear regression analysis of dose-response curves via GraphPad prism software (8.0).

**Culture and treatment of A549 cells**

Human ACE2 stable expressing A549 Alveolar Type II Lung Epithelial cells were cultured as previously described [16]. A549 cells were pre-treated for 30 minutes with RBM-derived peptides at 5 μM (final concentration, diluted in media), followed by 0.1 μM (final concentration) incubation with S_RBD-His protein (SARS-CoV-2 spike protein receptor binding domain, GenScript) for a further 3 hours.

**Western blot analysis**

Protein lysates were harvested from A549 cells using 1X RIPA buffer (25 mM Tris–HCl, 150 mM NaCl, 0.5% sodium deoxycholate, 1% NP-40, 1 mM DTT, 0.1% SDS; pH 7.5), supplemented with protease and phosphatase inhibitors (Roche). SDS sample buffer (10% SDS, 300mM Tris-HCl, 0.05% bromothymol blue, 10% β-mercaptoethanol) was used to dilute protein samples. Samples were boiled for 10 minutes at 70°C, and equal amounts of protein were loaded per well. Proteins were resolved on a 10% SDS-polyacrylamide gel, transferred to nitrocellulose membranes (GE Healthcare), stained with Ponceau-S (0.2% Ponceau-S red, 1% acetic acid) and blocked in 5% non-fat dry milk in 1X TBS-T (25mM, Tris-HCl; pH 7.6, 100 mM NaCl, 0.5% Tween-20).
Blocked membranes were incubated overnight at 4°C with α-polyhistidine (1:3000 dilution, Sigma, H1029), α-ACE2 (1:1000 dilution, Abcam, ab15348) or α-α tubulin (1:1000, Sigma, T9026) primary antibodies. Membranes were then incubated in near-infrared (IRDye) secondary antibody (1:5000 dilution, 925–68072 or 925–32213, Li-Cor Biosciences) for 1 hour at room temperature. Membranes were washed in 1X TBS-T following each antibody step. Densitymetry was carried out to measure fluorescent intensity of detected immunoreactive bands with Image Studio Lite (Licor Biosciences).

**Nano-luciferase fused ACE2 plasmid design**

Nano-luciferase (nLuc) internalisation assays are a well-established and robust system for studying receptor internalisation [24, 25]. The internalisation assay was performed using a plasmid encoding for the human ACE2 enzyme fused with a nano-luciferase at the N-terminus. pcDNA5-nLuc-ACE2 was generated from three different plasmids, pΔSfiI-ΔRFP-SCRPSY-ACE2 [16], pcDNA5-FFA4-YFP [26], and pcDNA5-nLuc mGPR91 (generously gifted of Dr Brian Hudson). The ACE2 (ACE2-F-KpnI, pcDNA3-R) and the nano-Luciferase (pcDNA-MCS-F and NLUC-R-KpnI) sequences were amplified using Phusion enzyme kit (cat F5305, ThermoFisher) with the primers in Table 1. Subsequently, pcDNA5-FFA4-YFP was digested with HindIII and XhoI. The pcDNA5 backbone plasmid and the two PCR products were then ligated in a three-piece ligation reaction following the T4 ligation manufactory instructions.

**Culture and transfection of HEK293T**

HEK293T cells were cultured in DMEM (Gibco) supplemented with 10% FBS (Gibco), 2mM L-glutamine (Gibco), 100U/I pen-strep (Gibco) and incubated at 5% CO₂, humified air, 37°C. Transient transfections were performed with polyethyleneimine (PEI, Cat#23966 Polysciences Inc.). Briefly, nLuc-ACE2 plasmid (1.5 μg per 80% confluent petri dish) and 9 μg PEI were incubated for 10 minutes in 0.9% NaCl solution at room temperature, prior to being added to the petri dish dropwise. 24-hours post-transfection, cells were seeded into poly-d-lysine coated (ThermoFisher) 96 well white plates (CellStar TC).

**Luminescence internalisation assay**

Transiently transfected HEK293T cells were washed and maintained in complete HBSS media (ThermoFisher) supplemented with 0.035% Sodium Bicarbonate (ThermoFisher) and 0.38% HEPES. HEK293T cells were then co-incubated for 2 hours with RBM-derived peptides (0.5, 5 or 50 μM, final concentrations) and 0.1 μM (final concentration) His-tagged SARS-CoV-2 Spike protein RBD (GenScript) or vehicle. Following 2-hour incubation period, HEK293T cells were further incubated for 10 minutes at 37°C with the nLuc substrate Nanoglo (Promega) prior to measurement of total luminescence with the BMG Clariostar tech plate reader. The internalisation of membrane bound nLuc-ACE2, induced by $S_{RBD}$ protein, is indirectly detected by a reduction in luminescence signal.

| Table 1. Primers. |
|-------------------|
| **Primers** | **Sequence** |
| pcDNA-MCS-F | TCCGGACTCTAGGGTTTAAACTAAAGCTT |
| NLUC-R-KpnI | TTTTTTGTACCAGCCAGAATGGTCG |
| ACE2-F-KpnI | TTTTTTGTACCTCAGCTCTCCGGCCTCT |
| pcDNA3-R | CGAGCTCTAGCATTTAGGGTGACACTATAG |

https://doi.org/10.1371/journal.pone.0260283.t001
SARS-CoV-2 spike protein–pseudovirus (PsV) neutralisation assay

As described previously [16], HEK293T cells stably expressing human ACE2 were seeded at 2x10^4 cells into each well of a white opaque 96 well tissue culture plate (Perkin Elmer) and pre-treated for 1 hour with (i) DMSO only, (ii) RBM peptide(s) at 600 μM, 200 μM, 60 μM, 30 μM, 6 μM or 2 μM, or (iii) soluble human ACE2 (sACE2) at 1 μM [25 μL total well volume]. Following this, 25 μL of the SARS CoV-2 S-protein (Wuhan-Hu-1 strain, spike trimer) expressing PsV (containing a luciferase reporter) was then added [50 μL total well volume] and plates were incubated at 37˚C, 5% CO₂ for 48 hours. Resultingly, this halved (1:1 dilution) the final concentrations of RBM peptide / sACE2 treatments. Finally, luciferase activity (Indicative of S-mediated PsV entry) was measured and PsV entry inhibition (neutralisation) was calculated as a percentage of DMSO only negative controls.

Cardiac microvascular endothelial cell culture and stimulation

Human coronary microvascular endothelial (CMEC) cells were cultured in endothelial growth medium MV2 (Promocell) until ~80% confluency. CMEC were serum starved 2 hours prior to any treatment(s) in DMEM containing 0.5% FBS. Following serum starving, cells were stimulated with 0.66 μg/mL (1 μg/10^6 cells) full-length recombinant SARS-CoV-2 S1 protein subunit (Cambridge Bioscience) for 5 hours. RBM peptides were pre-treated at 10 μM final concentration for 1 hour prior to S1 protein stimulation. Control cells were exposed to DMEM containing 0.5% FBS. Vehicle only control cells were pre-treated with 0.01% DMSO for 1 hour (same as RBM peptides). DMSO and RBM peptide treatments were diluted to appropriate concentrations in DMEM containing 0.5% FBS.

Real-time reverse-transcription polymerase chain reaction

Total RNA was isolated using QIAzol Lysis Reagent (Qiangen) according to manufacturer’s instructions and diluted in nuclease-free dH₂O (Ambion/Life Technologies). cDNA was generated from total RNA using the High-Capacity cDNA Reverse Transcription Kits (Applied Biosytems). Real-time polymerase chain reaction (PCR) was performed via a 7900HT Fast Real-Time PCR System (Applied Biosystems), using the SyBR Green Master Mix (Applied Biosystems) and human primers specific to (i) GAPDH, (ii) IL-1β, (iii) IL-6, (iv) MCP-1 and (v) VCAM (Eurofins Genomics). Relative gene expression was calculated by the 2^(-ΔΔCt) cycle threshold method as previously described [27].

Statistical analysis

Unless stated otherwise, all groups were analysed via a one-way ANOVA test. In the event a one-way ANOVA test measured statistical significance, follow up Dunnett’s or Tukey’s multiple comparison analysis was utilised to assess significance amongst groups. Where data was represented as MEAN ± SEM from N ≥ 3 independent experiments, results were determined significant by a p value < 0.05. All statistical analyses were carried out using GraphPad Prism 8.0 software

Results and discussion

Generation of SARS-CoV-2 receptor binding motif peptides capable of selectively binding ACE2

Observation of the co-crystal structure of the SARS-CoV-2 Spike glycoprotein in complex with the ACE2 receptor clearly demonstrates that the vast majority of known contact residues
to ACE2 exist within the N437–Y508 region of the viral protein, referred to as the receptor binding motif (RBM, corresponding to SARS-CoV-1 N424–Y494) [5–8]. Previous analysis of the SARS-CoV-2 RBM–ACE2 PPI interface pinpoint the formation of hydrogen bonds between known contact residues, with distance between interactions proposed to be between 2.6–3.6 Å [5–8]. Strikingly, the 25mer peptides S438–K462 (beginning of RBM) and E484–Y508 (end of RBM) include the majority of these contact residues (5 and 10 respectively), with the exclusion of A475 (Fig 1). Moreover, S438–K462 contains a Y451–L–Y–R–L–F456 hexapeptide sequence (Fig 2), corresponding to the known SARS-CoV-1 RBM hexapeptide.

Fig 2. Selecting a potential RBD–ACE2 PPI inhibitor peptide derived from SARS-CoV-2 RBM S438–K462 peptide. (A) N-terminal and (B) C-terminal stepwise truncation peptide array of RBM S438–K462, overlaid with ACE2-Fc human purified protein. Underlined (blue) sequence represents shorter sequence peptide selected for assessment in vitro. (C) Structure of S443–K458 SARS-CoV-2 RBM and the respective binding interface of ACE2 receptor; RBM interacting residues highlighted in red—adapted [7].

https://doi.org/10.1371/journal.pone.0260283.g002
(Y438 – K – Y – R – Y – L443) shown to directly bind ACE2 and induce antiviral activity in vitro [19]. Resultingly, these two 25mer peptides were rationally selected for peptide array screening aimed at discovery novel decoy peptides of the RBD–ACE2 PPI.

Soluble recombinant ACE2 (Q18 – S740 truncate, S1 Fig) was found to bind to both S438 – K462 (Fig 2) and E484 – Y508 (Fig 3) peptides using a far-western technique, (as indicated by

![Diagram](https://doi.org/10.1371/journal.pone.0260283.g003)

Fig 3. Selecting a potential RBD–ACE2 PPI inhibitor peptide derived from SARS-CoV-2 RBM E484 – Y508. (A) N-terminal and (B) C-terminal stepwise truncation peptide array of RBM E484 – Y508, overlaid with ACE2-Fc human purified protein. Underlined (blue) sequence represents shorter sequence peptide selected for assessment in vitro. (C) ACE2 binding to short sequence RBM 20mer; F486 – Y505. (D) Structure of F486 – Y505 SARS-CoV-2 RBM and the respective binding interface of ACE2 receptor; RBM interacting residues highlighted in red–adapted [7].

https://doi.org/10.1371/journal.pone.0260283.g003
the dark binding spots). Serial truncation of the N- and C-terminus of peptide S438 –K462 (Fig 2) suggested that (i) removal of S438 –D442 resulted in little reduction in ACE2 binding signal vs. control peptide (Fig 2A), and (ii) removal of S459 –K462 led to a noticeable increase in ACE2 binding signal (i.e., observable increase in peptide spot intensity, Fig 2B). As no known ACE2 contact residues were contained within these truncated sequences (determined through observation of known co-crystal structures), the S443 –K458 16mer truncated peptide was selected for follow up assessment in biophysical and cellular assays—now referred to as receptor binding motif peptide 1 (RBM1) (Fig 2C). Truncation analysis of peptide E484 –Y508 (Fig 3) suggested that removal of E484, G485 and Q506 –Y508 resulted in no observable reduction in ACE2 binding vs. control peptide (Fig 3A and 3B). Although none of these residues are known direct ACE2 contact residues, E484 remains a residue of interest due to E484-specific point mutations (e.g., E484K) being found to increase SARS-CoV-2 infectivity [28]. Consequently, E484 –Y508 (RBM2A, 25mer) and F486 –Y505 (RBM2B, 20mer) peptides were selected for biophysical and cellular in vitro assessment (Fig 3C and 3D).

To confirm target engagement of RBM-derived peptides (Table 2) with ACE2, FITC-labelled peptides were co-incubated with increasing concentrations of purified recombinant human ACE2-Fc (Q18 –S740, peptidase domain) protein (final concentration range: 0.012 nM– 6 μM, Fig 4). All three peptides demonstrated direct binding to ACE2, with binding affinities (Kd) in the high nM to low μM range (RBM1 Kd = 0.207 μM, RBM2A Kd = 1.13 μM, RBM2B Kd = 1.206 μM, N = 3, Fig 4A). No binding was observed with GST negative protein control, suggesting RBM peptides bound selectively to ACE2 (Fig 4B–4D). Although the RBM2A-Sc (RBM2A scrambled peptide negative control) appeared to bind to ACE2 in a dose-dependent manner (Fig 4C) saturation of ACE2 binding was not achieved and the data not interpreted via non-linear aggression analysis (GraphPad Prism 8.0). In total, the FP data suggested that we were successful in designing short sequence linear RBM-derived peptides capable of directly binding ACE2. Previous work using the peptide array approach has reliably generated highly-selective decoy peptides against pathological PPIs in a broad context of disease-indications, including heart failure (HSP20 –PDE4D) [29, 30], schizophrenia (DISC1 – FBWX7) [31], and cancer (c-Raf–PDE8A) [21, 32, 33]. All identified RBM peptides discovered in this study were tested as potential SARS-CoV-2 viral cell-entry inhibitors.

**RBM peptides do not prevent viral internalisation**

To assess the ability of RBM-derived peptides to inhibit SARS-CoV-2 spike protein-mediated internalisation, the peptides were initially tested against the spike protein receptor binding

**Table 2. ACE2 interacting SARS-CoV-2 RBM peptides.** Peptides synthesised with and without a C-terminal FITC tag.

| Peptide Name (Residues, Length) | Sequence | Mass (Da) | Purity (%) |
|---------------------------------|----------|-----------|------------|
| **RBM1 [S443 –K458]** | Ac-SKVGGNYNLRLFRK-NH₂ | 2019.34 | 99 |
| **RBM2A [E484-Y508]** | Ac-EGFNCYFPLQGQFTNGVQYQPY-NH₂ | 2918.19 | 99 |
|  | Ac-FNCYFPLQGQFTNGVQYQPY-NH₂ | 2343.60 | 99 |
| **RBM2A-Sc** | Ac-NYGLQSGFGQVQETPYPFNCNFVQYG-NH₂ | 2918.19 | 99 |
| **RBM1 (C-FITC)** | Ac-SKVGGNYNLRLFRK-K(FITC)-NH₂ | 2537.34 | 99 |
| **RBM2A (C-FITC)** | Ac-EGFNCYFPLQGQFTNGVQYQPY-K(FITC)-NH₂ | 3433.43 | 99 |
| **RBM2B (C-FITC)** | Ac-FNCYFPLQGQFTNGVQYQPY-K(FITC)-NH₂ | 2861.42 | 99 |
| **RBM2A-Sc (C-FITC)** | Ac-NYGLQSGFGQVQETPYPFNCNFVQYG-K(FITC)-NH₂ | 3433.43 | 99 |

See S2–S9 Figs for HPLC traces. RBM, receptor binding motif; Sc, scrambled.

https://doi.org/10.1371/journal.pone.0260283.t002
domain (S<sub>RBD</sub>) in an assay utilising ACE2 overexpressing A549 lung epithelial cells (Fig 5A). RBM1 (56.98% ± 20.67%, Lane 8), RBM2A (44.89% ± 17.37%, Lane 6) and RBM2B (43.22% ± 21.35%, Lane 7) all induced a marked, yet non-significant reduction in S<sub>RBD</sub>-mediated internalisation at 5 μM (Fig 5A). No significant difference was observed between RBM1, RBM2A and RBM2B. RBM-Sc did not significantly inhibit S<sub>RBD</sub>-mediated internalisation (94.19% ± 30.35%, Fig 5A, Lane 5). In an attempt to cover a larger segment of the PPI interface, a combination of RBM1 and RBM2B peptides was also tested, however, this did not potentiate the inhibitory effects observed with respective monotherapies (89.53% ± 47.23%, Fig 5A, Lane 9). Whether these peptides had an antagonistic effect on one another was not assessed.

RBM peptides were then tested against S<sub>RBD</sub>-mediated internalisation using a luciferase reporter ACE2 overexpressing HEK293T cell line (Fig 5B(i)). Recombinant S<sub>RBD</sub> (100 nM) induced internalisation resulting in a significant reduction in lucinescence signal (Fig 5B(ii), *** P < 0.001) observed on the cell surface. RBM2A and RBM2B, but not RBM1, appeared to partially rescue S<sub>RBD</sub>-mediated internalisation at 50 μM (not seen at 0.5 or 5 μM), as seen by a non-significant reduction in luminescence signal observed between vehicle treated and S<sub>RBD</sub>-treated conditions (Fig 5B, RBM2A: Blue–Lane 3, RBM2B: Orange–Lane 3). No significant difference was observed between RBM peptides.

It is worth noting that, even though (i) cells were pre-treated with RBM peptides prior to the application of S<sub>RBD</sub> (giving the peptides time to bind ACE2 without direct competition...
with $S_{\text{RBD}}$, and (ii) the concentration of RBM peptides was 5- to 500-fold higher than $S_{\text{RBD}}$ (100 nM), RBM peptides (alone or in combination) were unable to significantly abolish $S_{\text{RBD}}$ internalisation. These findings suggest that RBM1-2B are unable to effectively outcompete $S_{\text{RBD}}$ protein binding to ACE2.

Next, we attempted to evaluate the RBM peptides against the full-length spike trimer protein (Wuhan-Hu-1 strain) in an ACE2 overexpressing HEK293 pseudovirus (PsV) neutralisation assay (Fig 6). As expected, and previously demonstrated [16], soluble ACE2 protein completely blocked spike PsV cell entry at 0.5 μM. However, pre-treatment with RBM1, RBM2B or combined RBM1 and RBM2B did not inhibit PsV cell entry, even at a
concentration of 300 μM. These data suggest that the spike trimer can outcompete RBM-derived peptides for binding to ACE2, resulting in a lack of inhibitory activity.

Our findings, outlined above, strengthen the hypothesis that linear short sequence native RBM1-2B peptides represent a suboptimal approach to inhibiting ACE2-mediated SARS-CoV-2 host cell entry. Whether rational chemical modifications to the current structure of RBM1-2B peptides would significantly improve ACE2 binding affinity (and subsequent anti-viral activity), as seen with double stapled α1 helix ACE2-derived peptides vs. their respective linear analogues [18], remains unknown. It is worth noting that RBM peptides lack helical properties and are therefore not suitable candidates for peptide stapling. As such, other approaches (e.g., peptide cyclisation) should be considered as a potential way of improving RBM-peptides structure-activity-relationship. Furthermore, analysis of global genome sequencing datasets detailing identified mutations within the receptor binding domain have identified variants that possess higher ACE2 binding affinity (e.g., Y453F and N501Y) compared with the original Wuhan-1 strain [34, 35]. Resultingly, these mutations could be leveraged in future efforts aimed at selecting peptide sequences that possess higher ACE2 binding affinity. However, with picomolar SARS-CoV-2 ‘miniproteins’ demonstrating enhanced molecular interactions with ACE2 and potent anti-viral activity against SARS-CoV-2 [36], our data (and others like it [16–18]) further indicate that larger molecules with significantly higher ACE2 binding affinity represent a more apt approach to competitively blocking SARS-CoV-2 cell entry.

**RBM peptides do not inhibit S1 protein induced inflammation**

Finally, to determine whether our linear RBM peptides had the ability to perturb SARS-CoV-2 mediated inflammation (directly associated with the cytokine storm [37]) we tested them in a
SARS-CoV-2 RBM-derived peptides represent a suboptimal approach to blocking ACE2-mediated viral cell entry.
physiologically relevant human epithelial (CMEC) cell line that endogenously expresses ACE2. In these cells, S1 protein significantly upregulated mRNA expression of four pro-inflammatory markers associated with SARS-CoV-2 induced cytokine storm: IL-1β (Fig 7A, * P < 0.05, lanes 1–2), IL-6 (Fig 7B, * P < 0.05, lanes 1–2), VCAM (Fig 7C, **** P < 0.0001, lanes 1–2) and MCP-1 (Fig 7D, *** P < 0.001, lanes 1–2). RBM1 and RBM2B treatment (10 μM) did not mimic S1 protein-induced inflammation, indicating RBM peptides are not pro-inflammatory in this context (Fig 7A–7D, ns–not significant, lanes 3–6). Additionally, pre-treatment of cells with RBM1 or RBM2 did not attenuate the S1 induced inflammatory response (Fig 7, ns–not significant, lanes 7–9). In line with our other cellular assays (Figs 5 and 6), RBM peptide treatment concentrations (10 μM) were >100-fold higher than S1 protein (9 nM), reinforcing the notion that RBM peptides cannot effectively compete with S1 for binding to ACE2.

In summary, our work builds on the existing hypothesis that short linear peptide sequences derived from the native SARS-CoV-2 RBD–ACE2 PPI interface, represent a suboptimal therapeutic approach to blocking viral internalisation. Larger ligands (e.g., soluble ACE2, miniproteins, antibodies, nanobodies) that possess higher binding affinity for ACE2, robust stability and significantly enhanced secondary structure(s) are likely to confer superior antiviral efficacy, and future research should consider this when developing associated SARS-CoV-2 cell entry inhibitor therapeutics.

Supporting information

S1 Fig. Human purified recombinant ACE2-Fc (Q18-S740; GenScript), detected via SDS-PAGE by (left) Coomassie staining and (right) western immunoblotting with an αACE2 rabbit polyclonal antibody. Lane 1: Ladder, Lane 2: ACE2-Fc protein. ACE2-Fc protein detected at expected molecular weight (~110.5kDa).

S2 Fig. HPLC traces of RBM1 (S438-K462) on 2 gradients.

S3 Fig. HPLC traces of RBM2A (E484-Y508) on 2 gradients.

S4 Fig. HPLC traces of RBM2B (F486-Y505) on 2 gradients.

S5 Fig. HPLC traces of RBM2A-Scrambled on 2 gradients.

S6 Fig. HPLC traces of RBM1 (S438-K462)-FITC on 2 gradients.

S7 Fig. HPLC traces of RBM2A (E484-Y508)-FITC on 2 gradients.
S8 Fig. HPLC traces of RBM2B (F486-Y505)-FITC on 2 gradients.
(TIF)

S9 Fig. HPLC traces of RBM2A-scrambled-FITC on 2 gradients.
(TIF)

S1 Raw image.
(PDF)

S1 Data.
(XLSX)

S2 Data.
(XLSX)

S3 Data.
(XLSX)

S1 Dataset.
(PZFX)

S2 Dataset.
(PZFX)

Author Contributions

Formal analysis: Amit Mahindra, Gonzalo Tejeda, Mario Rossi, Omar Janha, Imogen Herbert, Caroline Morris, Danielle C. Morgan, Wendy Beattie, Augusto C. Montezano, Brian Hudson, Connor M. Blair.

Funding acquisition: Connor M. Blair.

Investigation: Amit Mahindra, Gonzalo Tejeda, Mario Rossi, Omar Janha, Imogen Herbert, Caroline Morris, Danielle C. Morgan, Wendy Beattie, Augusto C. Montezano, Brian Hudson, Connor M. Blair.

Methodology: Amit Mahindra, Gonzalo Tejeda, Mario Rossi, Omar Janha, Imogen Herbert, Caroline Morris, Danielle C. Morgan, Wendy Beattie, Augusto C. Montezano, Brian Hudson.

Project administration: Amit Mahindra, Connor M. Blair.

Supervision: Andrew B. Tobin, David Bhella, Rhian M. Touyz, Andrew G. Jamieson, George S. Baillie, Connor M. Blair.

Writing – original draft: Connor M. Blair.

Writing – review & editing: Amit Mahindra, Gonzalo Tejeda, Mario Rossi, Caroline Morris, Danielle C. Morgan, Andrew B. Tobin, David Bhella, Rhian M. Touyz, Andrew G. Jamieson, George S. Baillie, Connor M. Blair.

References

1. WHO (2021) Weekly Operational Update on COVID-19. Issue No. 75 (Last Reviewed: 12 October 2021)

2. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021; 19(3):141–54. https://doi.org/10.1038/s41579-020-00459-7 PMID: 33024307
3. Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends Immunol. 2020; 41(12):1100–15. https://doi.org/10.1016/j.it.2020.10.004 PMID: 33132005

4. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herliir T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271–80 e8. https://doi.org/10.1016/j.cell.2020.02.052 PMID: 32142651

5. Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020; 17(6):613–20. https://doi.org/10.1038/s41423-020-0400-4 PMID: 32203189

6. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020; 17(6):613–20. https://doi.org/10.1038/s41423-020-0400-4 PMID: 32203189

7. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271–80 e8. https://doi.org/10.1016/j.cell.2020.02.052 PMID: 32142651

8. Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020; 17(6):613–20. https://doi.org/10.1038/s41423-020-0400-4 PMID: 32203189

9. Yi C, Sun X, Ye J, Ding L, Liu M, Yang Z, et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol. 2020; 17(6):613–20. https://doi.org/10.1038/s41423-020-0458-z PMID: 32415260

10. Lu H, Zhou Q, He J, Jiang Z, Peng C, Tong R, et al. Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. Signal Transduct Target Ther. 2020; 5(1):213. https://doi.org/10.1038/s41392-020-00315-3 PMID: 32968059

11. Jones S, Thornton JM. Principles of protein-protein interactions. Proc Natl Acad Sci U S A. 1996; 93(1):13–20. https://doi.org/10.1073/pnas.93.1.13 PMID: 8552589

12. Scott DE, Bayly AR, Abell C, Skidmore J. Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Nat Rev Drug Discov. 2016; 15(8):533–50. https://doi.org/10.1038/nrd.2016.29 PMID: 27050677

13. Sorolla A, Wang E, Golden E, Duffy C, Henriques ST, Redfern AD, et al. Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics. Oncogene. 2020; 39(6):1167–84. https://doi.org/10.1038/s41388-019-1056-3 PMID: 31636882

14. de Vega MJ, Martin-Martinez M, Gonzalez-Muniz R. Modulation of protein-protein interactions by stabilizing/mimicking protein secondary structure elements. Curr Top Med Chem. 2007; 7(1):33–62. https://doi.org/10.2174/15680260779318325 PMID: 17266595

15. Brizzoni-Giovanelli H, Alezra V, Wolff N, Dong CZ, Tuffery P, Rebollo A. Interfering peptides targeting protein-protein interactions: the next generation of drugs? Drug Discov Today. 2018; 23(2):272–85. https://doi.org/10.1016/j.drudis.2017.10.016 PMID: 29097277

16. Morgan DC, Morris C, Mahindra A, Blair CM, Tejeda G, Herbert I, et al. Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalization. Pept Sci (Hoboken). 2021:e24217.

17. Karoyan P, Vieillard V, Gomez-Morales L, Odile E, Guihot A, Luyt CE, et al. Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary infections. Commun Biol. 2021; 4(1):197. https://doi.org/10.1038/s42003-021-01736-8 PMID: 33580154

18. Currell F, Victor SMB, Ahmed S, Drelich A, Tong X, Tseng CK, et al. Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection In Vitro. mBio. 2020; 11(6). https://doi.org/10.1128/mBio.02451-20 PMID: 33310780

19. Struck AW, Axmann M, Pfefferle S, Drosten C, Meyer B. A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2. Antiviral Res. 2012; 94(3):288–96. https://doi.org/10.1016/j.antiviral.2011.12.012 PMID: 22265858

20. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019 nCoV spike in the prefusion conformation. Science. 2020; 367(6485):1260–1263. https://doi.org/10.1126/science.abb2507 PMID: 32075877

21. Brown KM, Day JP, Huston E, Zimmermann B, Hampel K, Christian F, et al. Phosphodiesterase-8A binds to and regulates Raf-1 kinase. Proc Natl Acad Sci U S A. 2013; 110(16):E1533–42. https://doi.org/10.1073/pnas.1303041110 PMID: 23509299

22. Frank R. Spot-synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support. Tetrahedron. 1992; 48(42):9217–32.
23. Amartely H, Losub-Amit A, Friedler A. Identifying protein-protein interaction sites using peptide arrays. J Vis Exp. 2014; 18(93):e52097. https://doi.org/10.3791/52097 PMID: 25490271

24. Liu Y, Song G, Shao XX, Liu YL, Guo ZY. Quantitative measurement of cell membrane receptor internalization by the nanoluciferase reporter: Using the G protein-coupled receptor RXFP3 as a model. Biochim Biophys Acta. 2015; 1848(2):688–694. https://doi.org/10.1016/j.bbamem.2014.11.026 PMID: 25434927

25. Robers MW, Binkowski BF, Cong M, Zimprich C, McDonough M, et al. A luminescent assay for real-time measurements of receptor endocytosis in living cells. AnalBiochem. 2015; 489:1–8. https://doi.org/10.1016/j.ab.2015.08.005 PMID: 26278171

26. Prihandoko R, Alvarez-Curto E, Hudson BD, Butcher AJ, Ulven T, Miller AM, et al. Distinct Phosphorylation Clusters Determine the Signaling Outcome of Free Fatty Acid Receptor 4/G Protein-Coupled Receptor 120. Mol Pharmacol. 2016; 89(5):505–20. https://doi.org/10.1124/mol.115.101949 PMID: 26673857

27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25:402–408. https://doi.org/10.1006/meth.2001.1262 PMID: 11846609

28. Khan A, Zia T, Suleman M, Khan T, Ali SS, Abbasi AA, et al. Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data. J Cell Physiol. 2021.

29. Sin YY, Edwards HV, Li X, Day JP, Christian F, Dunlop AJ, et al. Disruption of the cyclic AMP phosphodiesterase-4 (PDE4)-HSP20 complex attenuates the beta-agonist induced hypertrophic response in cardiac myocytes. J Mol Cell Cardiol. 2011; 50(5):872–83 https://doi.org/10.1016/j.yjmcc.2011.02.006 PMID: 21334344

30. Martin TP, Hortigon-Vinagre MP, Findlay JE, Elliott C, Currie S, Baillie GS. Targeted disruption of the heat shock protein 20 phosphodiesterase 4D (PDE4D) interaction protects against pathological cardiac remodelling in a mouse model of hypertrophy. FEBS Open Bio. 2014; 4:923–7. https://doi.org/10.1016/j.fob.2014.10.011 PMID: 25426411

31. Yalla K, Elliott C, Day JP, Findlay J, Barratt S, Hughes ZA, et al. FBXW7 regulates DISC1 stability via the ubiquitin-proteosome system. Mol Psychiatry. 2018; 23(5):1279–86. https://doi.org/10.1038/mp.2017.138 PMID: 28727686

32. Basole CP, Nguyen RK, Lamonte K, Vang A, Clark R, Baillie GS, et al. PDE8 controls CD4(+) T cell motility through the PDEBA-Raf-1 kinase signaling complex. Cell Signal. 2017; 40:62–72. https://doi.org/10.1016/j.cellsig.2017.08.007 PMID: 28651628

33. Blair CM, Walsh NM, Littman BH, Marcoux FW, Baillie GS. Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A -C-Raf. BMC Cancer. 2019; 19(1):266. https://doi.org/10.1186/s12885-019-5489-4 PMID: 30909892

34. Guruprasad L. Human SARS CoV-2 spike protein mutations. Proteins. 2021; 89(5):569–576. https://doi.org/10.1002/prot.26042 PMID: 33423311

35. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. 2021; 19(7):409–424.

36. Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, et al. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science. 2020; 370(6515):426–31. https://doi.org/10.1126/science.abc9090 PMID: 32907861

37. Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther. 2021; 6(1):255. https://doi.org/10.1038/s41392-021-00679-0 PMID: 34234112